Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease: FUTURE-I

NCT02659254 is registered in ClinicalTrials.gov with Shanghai MicroPort Medical (Group) Co., Ltd. as lead sponsor.

NCT NCT02659254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02659254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease: FUTURE-I
Lead sponsor
Shanghai MicroPort Medical (Group) Co., Ltd.
Phase
Not applicable
Overall status
Completed
Start date
January 31, 2016
Completion date
March 31, 2021
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease